Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jan;28(1):205-210.
doi: 10.1177/10781552211013878. Epub 2021 May 14.

Bendamustine-induced nephrogenic diabetes insipidus - A case report

Audrey Desjardins  1 , Viviane Le-Nguyen  1 , Léa Turgeon-Mallette  1 , Chloé Vo  1 , Jean-Samuel Boudreault  2 , Jean-Philippe Rioux  3 , Xue Feng  4 , Amélie Veilleux  4
Affiliations
Case Reports

Bendamustine-induced nephrogenic diabetes insipidus - A case report

Audrey Desjardins et al. J Oncol Pharm Pract. 2022 Jan.

Abstract

Introduction: In patients with relapsed or refractory lymphoma, high-dose chemoimmunotherapy with subsequent autologous hematopoietic cell transplantation (HCT) is a standard of care. Bendamustine, an alkylating agent, is used in the BeEAM (bendamustine, etoposide, cytarabine, melphalan) protocol for conditioning therapy before autologous HCT in patients with relapsed or refractory lymphoma who are eligible for transplant. There is no consensus regarding an optimal salvage regimen and the approach varies according to toxicity.

Case report: We present a case of partial nephrogenic diabetes insipidus after receiving bendamustine, as part of the BeEAM protocol.Management and outcome: The patient was managed with parenteral fluid administration and intranasal desmopressin before the condition resolved on its own.

Discussion: We summarize published reports of bendamustine-induced diabetes insipidus.

Keywords: Bendamustine; adverse effect; diabetes insipidus; nephrogenic diabetes insipidus.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: JSB has served on advisory boards for Janssen, Celgene, Amgen, and BMS.

Figures

Figure 1.
Figure 1.
Serum sodium and urine output during hospitalization.H*: D5% + 1/2 NS + KCl 20 mEq alternating with NS + KCl 20 mEq.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Rummel MJ, Niederle N, Maschmeyer G, et al.. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203–1210. - PubMed
    1. Flinn IW, van der Jagt R, Kahl BS, et al.. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL of MCL: the BRIGHT study. Blood 2014; 123: 2944–2952. - PMC - PubMed
    1. Garnock-Jones KP. Bendamustine: a review of its use in the management of indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. Drugs 2010; 70: 1703–1718. - PubMed
    1. Visani G, Malerba L, Stefani PM, et al.. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 2011; 118: 3419–3425. - PubMed
    1. Kumar L, Ganessan P, Ghosh I, et al.. Autologous blood stem cell transplantation for hodgkin and non-Hodgkin lymphoma: complications and outcome. Natl Med J India 2010; 23: 330–335. - PubMed

Publication types

MeSH terms